Stefania Meschini Selected Research

voacamine

1/2022	A natural product, voacamine, sensitizes paclitaxel-resistant human ovarian cancer cells.
6/2020	Voacamine: Alkaloid with its essential dimeric units to reverse tumor multidrug resistance.
1/2019	Influence of lipid composition on the ability of liposome loaded voacamine to improve the reversion of doxorubicin resistant osteosarcoma cells.
11/2015	High-performance thin-layer chromatography for the evaluation of voacamine intracellular concentration related to its cytotoxic effect.
4/2014	Voacamine modulates the sensitivity to doxorubicin of resistant osteosarcoma and melanoma cells and does not induce toxicity in normal fibroblasts.
11/2008	The plant alkaloid voacamine induces apoptosis-independent autophagic cell death on both sensitive and multidrug resistant human osteosarcoma cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stefania Meschini Research Topics

Disease

11	Neoplasms (Cancer) 01/2022 - 05/2003
5	Osteosarcoma (Osteogenic Sarcoma) 06/2020 - 11/2008
4	Melanoma (Melanoma, Malignant) 01/2020 - 02/2004
2	Colonic Neoplasms (Colon Cancer) 01/2022 - 09/2012
2	Colorectal Neoplasms (Colorectal Cancer) 11/2021 - 10/2019
2	Carcinoma (Carcinomatosis) 10/2019 - 03/2009
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2007 - 05/2003
1	Ovarian Neoplasms (Ovarian Cancer) 01/2022
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 07/2021
1	Hematologic Neoplasms (Hematological Malignancy) 03/2018
1	Cicatrix (Scar) 09/2012
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2012
1	Phototoxic Dermatitis (Phototoxicity) 03/2009
1	Lung Neoplasms (Lung Cancer) 05/2008
1	Breast Neoplasms (Breast Cancer) 04/2006
1	Adenocarcinoma 04/2006

Drug/Important Bio-Agent (IBA)

9	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 05/2003
7	Pharmaceutical PreparationsIBA 01/2022 - 05/2003
6	voacamineIBA 01/2022 - 11/2008
5	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 01/2022 - 05/2003
4	AlkaloidsIBA 06/2020 - 11/2008
2	Biological ProductsIBA 01/2022 - 11/2008
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2022
1	Fluorouracil (Carac)FDA LinkGeneric 01/2022
1	AntioxidantsIBA 11/2021
1	Mitomycin (Mitomycin-C)FDA LinkGeneric 07/2021
1	voacangineIBA 06/2020
1	vobasineIBA 06/2020
1	CelluloseIBA 01/2020
1	Cytostatic AgentsIBA 01/2020
1	HydrogelsIBA 01/2020
1	CationsIBA 01/2020
1	PhytochemicalsIBA 10/2019
1	Liposomes (Liposome)IBA 01/2019
1	LipidsIBA 01/2019
1	SuspensionsIBA 09/2012
1	InterferonsIBA 01/2012
1	DNA (Deoxyribonucleic Acid)IBA 01/2012
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2012
1	Interferon Type IIBA 01/2012
1	Troglitazone (Rezulin)FDA Link 01/2012
1	early endosome antigen 1IBA 12/2009
1	AntigensIBA 12/2009
1	Reactive Oxygen Species (Oxygen Radicals)IBA 03/2009
1	TetrapyrrolesIBA 03/2009
1	Singlet OxygenIBA 03/2009
1	Small Interfering RNA (siRNA)IBA 11/2008
1	TubulinIBA 05/2008
1	Caspase 3 (Caspase-3)IBA 01/2007
1	StilbenesIBA 01/2007
1	combretastatinIBA 01/2007
1	tempolIBA 04/2006
1	AnthracyclinesIBA 04/2006
1	nitroxylIBA 04/2006
1	piperidineIBA 04/2006
1	Tea Tree OilIBA 02/2004
1	terpinenol-4IBA 02/2004
1	Proteins (Proteins, Gene)FDA Link 05/2003

Therapy/Procedure

4	Therapeutics 01/2020 - 04/2014
3	Drug Therapy (Chemotherapy) 01/2022 - 05/2003
1	Photochemotherapy (Photodynamic Therapy) 01/2020